vs

Side-by-side financial comparison of BICYCLE THERAPEUTICS PLC (BCYC) and Clearfield, Inc. (CLFD). Click either name above to swap in a different company.

BICYCLE THERAPEUTICS PLC is the larger business by last-quarter revenue ($48.0M vs $34.3M, roughly 1.4× Clearfield, Inc.). Clearfield, Inc. runs the higher net margin — -1.8% vs -42.0%, a 40.2% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs -3.2%). Clearfield, Inc. produced more free cash flow last quarter ($-2.4M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs -3.5%).

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.

BCYC vs CLFD — Head-to-Head

Bigger by revenue
BCYC
BCYC
1.4× larger
BCYC
$48.0M
$34.3M
CLFD
Growing faster (revenue YoY)
BCYC
BCYC
+1196.5% gap
BCYC
1193.3%
-3.2%
CLFD
Higher net margin
CLFD
CLFD
40.2% more per $
CLFD
-1.8%
-42.0%
BCYC
More free cash flow
CLFD
CLFD
$17.5M more FCF
CLFD
$-2.4M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
-3.5%
CLFD

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCYC
BCYC
CLFD
CLFD
Revenue
$48.0M
$34.3M
Net Profit
$-20.2M
$-614.0K
Gross Margin
33.2%
Operating Margin
-51.5%
-5.3%
Net Margin
-42.0%
-1.8%
Revenue YoY
1193.3%
-3.2%
Net Profit YoY
61.1%
67.8%
EPS (diluted)
$-0.29
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCYC
BCYC
CLFD
CLFD
Q4 25
$48.0M
$34.3M
Q3 25
$11.7M
$23.4M
Q2 25
$2.9M
$49.9M
Q1 25
$10.0M
$47.2M
Q4 24
$3.7M
$29.7M
Q3 24
$2.7M
$5.6M
Q2 24
$9.4M
$48.8M
Q1 24
$19.5M
$36.9M
Net Profit
BCYC
BCYC
CLFD
CLFD
Q4 25
$-20.2M
$-614.0K
Q3 25
$-59.1M
$-9.1M
Q2 25
$-79.0M
$1.6M
Q1 25
$-60.8M
$1.3M
Q4 24
$-1.9M
Q3 24
$-50.8M
Q2 24
$-39.8M
$-447.0K
Q1 24
$-26.6M
$-5.9M
Gross Margin
BCYC
BCYC
CLFD
CLFD
Q4 25
33.2%
Q3 25
53.2%
Q2 25
30.5%
Q1 25
30.1%
Q4 24
29.2%
Q3 24
Q2 24
21.9%
Q1 24
7.7%
Operating Margin
BCYC
BCYC
CLFD
CLFD
Q4 25
-51.5%
-5.3%
Q3 25
-558.6%
10.3%
Q2 25
-2965.8%
3.0%
Q1 25
-703.7%
0.6%
Q4 24
-6.9%
Q3 24
-2385.9%
Q2 24
-498.3%
-4.7%
Q1 24
-162.4%
-26.4%
Net Margin
BCYC
BCYC
CLFD
CLFD
Q4 25
-42.0%
-1.8%
Q3 25
-503.7%
-38.8%
Q2 25
-2703.8%
3.2%
Q1 25
-608.9%
2.8%
Q4 24
-6.4%
Q3 24
-1898.4%
Q2 24
-425.3%
-0.9%
Q1 24
-136.0%
-16.0%
EPS (diluted)
BCYC
BCYC
CLFD
CLFD
Q4 25
$-0.29
$-0.04
Q3 25
$-0.85
$-0.65
Q2 25
$-1.14
$0.11
Q1 25
$-0.88
$0.09
Q4 24
$-0.13
Q3 24
$-0.74
Q2 24
$-0.77
$-0.04
Q1 24
$-0.62
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCYC
BCYC
CLFD
CLFD
Cash + ST InvestmentsLiquidity on hand
$628.1M
$96.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$610.0M
$249.7M
Total Assets
$717.6M
$268.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCYC
BCYC
CLFD
CLFD
Q4 25
$628.1M
$96.4M
Q3 25
$648.3M
$106.0M
Q2 25
$721.5M
$117.2M
Q1 25
$793.0M
$112.0M
Q4 24
$879.5M
$113.0M
Q3 24
$890.9M
$129.0M
Q2 24
$961.4M
$123.8M
Q1 24
$457.0M
$142.9M
Total Debt
BCYC
BCYC
CLFD
CLFD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$2.2M
Q2 24
$30.9M
$2.1M
Q1 24
$30.8M
Stockholders' Equity
BCYC
BCYC
CLFD
CLFD
Q4 25
$610.0M
$249.7M
Q3 25
$618.5M
$256.2M
Q2 25
$668.9M
$264.5M
Q1 25
$740.3M
$265.9M
Q4 24
$793.1M
$267.4M
Q3 24
$831.0M
$275.8M
Q2 24
$873.8M
$274.6M
Q1 24
$356.0M
$279.2M
Total Assets
BCYC
BCYC
CLFD
CLFD
Q4 25
$717.6M
$268.1M
Q3 25
$764.0M
$306.2M
Q2 25
$832.2M
$314.7M
Q1 25
$883.9M
$310.9M
Q4 24
$956.9M
$303.2M
Q3 24
$996.7M
$315.3M
Q2 24
$1.1B
$318.1M
Q1 24
$547.1M
$315.4M
Debt / Equity
BCYC
BCYC
CLFD
CLFD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.01×
Q2 24
0.04×
0.01×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCYC
BCYC
CLFD
CLFD
Operating Cash FlowLast quarter
$-19.3M
$-1.4M
Free Cash FlowOCF − Capex
$-19.9M
$-2.4M
FCF MarginFCF / Revenue
-41.5%
-7.1%
Capex IntensityCapex / Revenue
1.2%
2.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-252.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCYC
BCYC
CLFD
CLFD
Q4 25
$-19.3M
$-1.4M
Q3 25
$-71.2M
Q2 25
$-72.8M
$7.9M
Q1 25
$-86.4M
$3.0M
Q4 24
$-164.7M
$7.2M
Q3 24
$-39.8M
$22.2M
Q2 24
$-44.6M
$4.0M
Q1 24
$-70.9M
$-5.7M
Free Cash Flow
BCYC
BCYC
CLFD
CLFD
Q4 25
$-19.9M
$-2.4M
Q3 25
$-71.8M
Q2 25
$-73.3M
$7.5M
Q1 25
$-87.0M
$654.0K
Q4 24
$-166.0M
$5.1M
Q3 24
$-40.3M
$18.2M
Q2 24
$-45.0M
$2.8M
Q1 24
$-70.9M
$-7.7M
FCF Margin
BCYC
BCYC
CLFD
CLFD
Q4 25
-41.5%
-7.1%
Q3 25
-612.3%
Q2 25
-2509.7%
15.1%
Q1 25
-871.7%
1.4%
Q4 24
-4475.7%
17.1%
Q3 24
-1504.7%
323.0%
Q2 24
-481.2%
5.8%
Q1 24
-362.9%
-20.8%
Capex Intensity
BCYC
BCYC
CLFD
CLFD
Q4 25
1.2%
2.9%
Q3 25
5.7%
2.0%
Q2 25
17.1%
0.8%
Q1 25
6.1%
5.1%
Q4 24
33.3%
7.0%
Q3 24
16.3%
71.4%
Q2 24
4.5%
2.5%
Q1 24
0.1%
5.3%
Cash Conversion
BCYC
BCYC
CLFD
CLFD
Q4 25
Q3 25
Q2 25
4.93×
Q1 25
2.30×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons